Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(157 produtos)
- Bcr-Abl(113 produtos)
- EGFR(596 produtos)
- FAK(72 produtos)
- FLT(88 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(180 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2002 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3K/VEGFR2-IN-1
CAS:PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.Fórmula:C17H14ClN3OSPureza:98%Cor e Forma:SolidPeso molecular:343.83BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Fórmula:C26H23N7O2Cor e Forma:SolidPeso molecular:465.51BCR-ABL-IN-4
CAS:BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).Fórmula:C27H24ClF2N5O4Cor e Forma:SolidPeso molecular:555.96PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Fórmula:C19H22ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:431.88BPR1J-340
CAS:BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.Fórmula:C29H34N8O3Cor e Forma:SolidPeso molecular:542.63Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Fórmula:C25H26ClFN4O4Pureza:99.7%Cor e Forma:SolidPeso molecular:500.95PonatiLink-1-24
CAS:Ponatinib, also known as PonatiLink-1-24, is a selective inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Fórmula:C101H144ClF5N12O29Cor e Forma:SolidPeso molecular:2120.73OTS447
CAS:OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .Fórmula:C27H32ClN3O2Pureza:98.78%Cor e Forma:SolidPeso molecular:466.02Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Fórmula:C21H33F3N6O11Pureza:98%Cor e Forma:SolidPeso molecular:602.521JNJ-17029259
CAS:JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).Fórmula:C26H30N6OPureza:98%Cor e Forma:SolidPeso molecular:442.56DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Fórmula:C60H77Cl2N13O3SCor e Forma:SoildPeso molecular:1131.31JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Fórmula:C20H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:380.44FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Fórmula:C25H24N6O2SCor e Forma:SolidPeso molecular:472.56JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Fórmula:C33H41ClN8O2Pureza:98.75%Cor e Forma:SolidPeso molecular:617.18BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFórmula:C29H24N4O4SPureza:98.38%Cor e Forma:SolidPeso molecular:524.59PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Fórmula:C22H21ClN6O2Cor e Forma:SolidPeso molecular:436.89Roslin 2 bromide
CAS:Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.Fórmula:C13H19BrN4Pureza:99.34%Cor e Forma:SolidPeso molecular:311.22JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:488.35Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Fórmula:C30H37N7O2Cor e Forma:SolidPeso molecular:527.66Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFórmula:C26H21F2N5O3Pureza:99.41%Cor e Forma:SolidPeso molecular:489.47TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Cor e Forma:SolidPeso molecular:512.43ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Fórmula:C27H34ClN7O3SPureza:98%Cor e Forma:SolidPeso molecular:572.12Famitinib malate
CAS:Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.Fórmula:C27H33FN4O7Cor e Forma:SolidPeso molecular:544.57SIM010603
CAS:SIM010603, an oral RTK inhibitor, targets Kit, VEGFR-2, PDGFR-β, RET, FLT3 (IC50: 5.0-68.1 nmol/l), inhibits cell proliferation and angiogenesis.Fórmula:C22H25FN4O2Cor e Forma:SolidPeso molecular:396.46PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Fórmula:C23H18ClF2N3O2SPureza:98.84%Cor e Forma:SolidPeso molecular:473.92FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:442.523BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2TIE-2/VEGFR-2 kinase-IN-5
CAS:TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.Fórmula:C21H13F6N5O2Pureza:99.79%Cor e Forma:SolidPeso molecular:481.35ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Fórmula:C27H34ClN7O3SCor e Forma:SolidPeso molecular:572.12EGFR mutant-IN-1
EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.Fórmula:C34H39ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:632.17HDAC/JAK/BRD4-IN-1
CAS:HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.Fórmula:C24H28N6O3Pureza:98%Cor e Forma:SolidPeso molecular:448.52BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Fórmula:C20H22Cl2N6OCor e Forma:SolidPeso molecular:433.33ALK/EGFR-IN-3
CAS:ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-Fórmula:C27H34ClN7O3SCor e Forma:SolidPeso molecular:572.12VEGFR2-IN-3
CAS:VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].Fórmula:C26H28ClN5O4Pureza:98%Cor e Forma:SolidPeso molecular:509.98BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Fórmula:C27H28ClFN8O3Pureza:99.98%Cor e Forma:SolidPeso molecular:567.01Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFórmula:C22H20N6O3Cor e Forma:SolidPeso molecular:416.43GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Fórmula:C24H26N2O2Cor e Forma:SolidPeso molecular:374.48JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Fórmula:C19H17N5O4Pureza:98%Cor e Forma:SolidPeso molecular:379.37TIE-2/VEGFR-2 kinase-IN-3
CAS:TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 valuesFórmula:C23H17F4N5O3SCor e Forma:SolidPeso molecular:519.47DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56UNC5293
CAS:UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.Fórmula:C30H42N6O2Cor e Forma:SolidPeso molecular:518.69T338C Src-IN-1
CAS:T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).Fórmula:C17H20N6O2SPureza:98%Cor e Forma:SolidPeso molecular:372.44Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Pureza:95%Cor e Forma:LiquidVEGFR-2-IN-37
CAS:VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.Fórmula:C18H16N2O2SPureza:98%Cor e Forma:SolidPeso molecular:324.4EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.68Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Fórmula:C18H21N5O3Pureza:99.85%Cor e Forma:SolidPeso molecular:355.39BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Fórmula:C37H42N8O4Cor e Forma:SolidPeso molecular:662.78(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43GW-6604
CAS:GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.Fórmula:C19H14N4Pureza:99.6%Cor e Forma:SolidPeso molecular:298.34EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97
